Author

S. Kamle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 8 Organism:human· 8 Research Focus:drug response / drug discovery· 4 Assay:proteomics· 4 Approach:statistical model· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

J. A. Elias· 9 shared C. G. Lee· 8 shared C.-M. Lee· 7 shared B. Ma· 6 shared B. Akosman· 5 shared G. Schor· 2 shared H. Khan· 2 shared J. H. Lee· 2 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersImmunology

J. A. Elias

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Chitinase 3-like-1 (CHI3L1) Inhibits Innate Anti-Tumor and Tissue Remodeling ImmuneResponses by Regulating CD47-SIRPα and CD24-Siglec10-Mediated Phagocytosis

B. Ma, S. Kamle, C.-M. Lee, J. H. Lee, D. C. Yee, Z. Zhu, E. K. Silverman, D. DeMeo, A. M. K. Choi, C. G. Lee, J. A. Elias

This study shows CHI3L1 inhibits macrophage phagocytosis by modulating CD47-SIRPα and CD24-Siglec10 pathways, contributing to immune evasion in cancer and COPD.

bioRxiv · Dec 27, 2023 · PreprintImmunology

Chitinase 3-like-1 (CHI3L1) in the Pathogenesis of Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer

S. Kamle, B. Ma, G. Schor, M. Bailey, B. Pham, I. Cho, H. Khan, C. Azzoli, M. Hofstetter, C.-M. Lee, R. Herbst, K. Politi, C. G. Lee, J. A. Elias

This study shows CHI3L1 is induced by EGFR activation in NSCLC and promotes EGFR signaling, with anti-CHI3L1 antibodies reversing TKI resistance and inhibiting metastasis.

bioRxiv · Sep 21, 2023Cancer Biology

CHI3L1 Enhances Melanoma Lung Metastasis via Regulation of T cell Co-stimulators and CTLA-4/B7 Axis

B. Ma, S. Kamle, B. Akosman, H. Khan, C.-M. Lee, C. G. Lee, J. A. Elias

This study shows CHI3L1 promotes melanoma lung metastasis by inhibiting T cell co-stimulators and stimulating CTLA-4/B7 axis, with combined anti-CHI3L1 and anti-CTLA-4 antibodies showing synergistic antitumor effects.

bioRxiv · Jun 23, 2022Immunology

Host Chitinase 3-like-1 is a Universal Therapeutic Target for SARS-CoV-2 Viral Variants in COVID 19

S. Kamle, B. Ma, C. M. Lee, G. Schor, Y. Zhou, C. G. Lee, J. A. Elias

This study shows that targeting CHI3L1 inhibits SARS-CoV-2 variants' infection of epithelial cells, suggesting it as a universal therapeutic target.

bioRxiv · Jan 21, 2022Immunology

Chi3l1 is a modulator of glioma stem cell states and a therapeutic vulnerability for glioblastoma

C. Guetta-Terrier, D. Karambizi, B. Akosman, J.-S. Chen, S. Kamle, J. E. Fajardo, A. Fiser, R. Singh, S. A. Toms, C. G. Lee, J. A. Elias, N. Tapinos

This study shows Chi3l1 modulates glioma stem cell states by altering transcription factor activity and cell state transitions, and demonstrates anti-Chi3l1 antibody treatment inhibits glioblastoma growth.

bioRxiv · Oct 1, 2021 · PreprintCancer Biology

Kasugamycin is a novel chitinase 1 inhibitor with strong antifibrotic effects on pulmonary fibrosis

J.-H. Lee, C.-M. Lee, J. H. Lee, M.-O. Kim, J. W. Park, S. Kamle, B. Akosman, E. L. Herzog, X. Y. Peng, J. A. Elias, C. G. Lee

This study identifies Kasugamycin as a novel CHIT1 inhibitor with strong antifibrotic effects in pulmonary fibrosis models.

bioRxiv · Feb 25, 2021Immunology

Chitinase 3-like-1 Stimulates PD-L1 and Other Immune Checkpoint Inhibitors

B. Ma, B. Akosman, S. Kamle, C.-M. Lee, J. S. Koo, C. G. Lee, J. A. Elias

This study shows Chi3l1 promotes PD-L1 and other immune checkpoint inhibitors in melanoma, suggesting combined targeting of Chi3l1 and PD-1-PD-L1 as a therapeutic strategy for pulmonary metastasis.

bioRxiv · Jan 15, 2021 · PreprintCancer Biology

Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19

S. Kamle, B. Ma, C. H. He, B. Akosman, Y. Zhou, C.-M. Lee, W. S. El-Deiry, K. Huntington, O. Liang, J. T. Machan, M.-J. Kang, H. J. Shin, E. Mizoguchi, C. G. Lee, J. A. Elias

This study identifies CHI3L1 as a key mediator of aging-related severity in COVID-19 by stimulating ACE2 and SPP expression, and shows it is a therapeutic target.

bioRxiv · Jan 5, 2021Immunology

Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells

L. Zhou, K. Huntington, S. Zhang, L. Carlsen, E.-Y. So, C. Parker, I. Sahin, H. Safran, S. Kamle, C.-M. Lee, C.-G. Lee, J. A. Elias, K. S. Campbell, M. T. Naik, W. J. Atwood, , W. El-Deiry

This study shows MEK inhibitors reduce ACE2 and inflammatory cytokines, enhance NK cell activity, and block SARS-CoV-2 pseudovirus infection in human cells.

bioRxiv · Aug 2, 2020 · PreprintCell Biology